Search results
Showing 46 to 60 of 70 results for crohn's disease
prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas Number CG118 Date issued March 2011
genetic markers, for colorectal cancer in people with inflammatory bowel disease (IBD) or adenomas. Research should be undertaken to...
there is some observational evidence in people with inflammatory bowel disease (IBD), there is no evidence in people after adenoma...
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
This guidance has been updated and replaced by NICE guideline NG129.
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
We have moved interventional procedures guidance 288 to become HealthTech guidance 182. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Filgotinib for treating moderately to severely active Crohn's disease [ID6236]
Discontinued Reference number: GID-TA11244
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)
We have moved Diagnostics guidance 45 to become HealthTech guidance 610. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)
This guidance has been updated and replaced by NICE technology appraisal guidance 187.
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.
View recommendations for TA160Show all sections
Find out more about the NICE technology appraisal advisory committee B members and their registered interests